

Comment on the case report “Possible association between acetazolamide administration during pregnancy and multiple congenital malformations”

Elif Keskin-Arslan^{1,2}

Yusuf Cem Kaplan^{1,2}

¹Department of Pharmacology, School of Medicine, Izmir Katip Celebi University, ²Terafar – Izmir Katip Celebi University Teratology Information, Training and Research Center, Izmir, Turkey

Dear editor

We read with interest the case report in the April 2016 issue of *Drug Design Development and Therapy* by Al-Saleem and Al-Jobair.¹ The authors have presented a boy with oligodontia, ectrodactyly, and syndactyly who was exposed to acetazolamide in utero. Although the discussion was well balanced with a mention to possible confounders such as family and obstetric history and lack of a genetic analysis, two important papers regarding prenatal exposure to acetazolamide were not cited by the authors. In this letter, we would like to mention these studies in order to expand the current context provided by Al-Saleem and Al-Jobair.¹

Scott et al suggested that non-rodent species such as monkeys² were shown to be resistant to the forelimb reduction inducing effect of acetazolamide that was seen in the offspring of rodents^{3,4} (mice, rat, hamster) which were prenatally exposed to this agent. Low carbonic anhydrase enzyme activity in this species during the sensitive period of development or poor bioavailability/passage of the drug was proposed as the mechanism of resistance to the aforementioned effects.²

Heinonen et al⁵ have evaluated and presented the outcomes of the largest number of pregnant women exposed to acetazolamide during their pregnancies. The authors included 1,024 mothers who used acetazolamide anytime during pregnancy and reported 18 infants with a malformation, a result that was not higher than the expected value (18.06) (relative risk 1.00, 95% confidence interval 0.59–1.57). However, the number of the exposures in the sensitive period of development was low; there were only 13 mother and child pairs who were exposed to carbonic anhydrase inhibitors (12 pairs to acetazolamide and one pair to ethoxzolamide) during 1–4 gestation months and none of them had any malformation. Finally, we are in agreement with the suggestion of Al-Saleem and Al-Jobair¹ regarding the verification of the absence of pregnancy before initiating acetazolamide to women of reproductive age. Nevertheless, the successful use of acetazolamide has been described in a limited number of pregnant women with intracranial hypertension.^{6,7} As previously remarked by Falardeau et al, clinicians should be aware that “The avoidance of acetazolamide during the first trimester has very little medical justification and is mainly guided by medical–legal rationale”.⁷ Therefore, each pregnant patient should be counseled individually with a careful risk–benefit assessment regarding the necessity of acetazolamide treatment during pregnancy in order to ensure the appropriate management of their diseases.

Correspondence: Yusuf Cem Kaplan
Izmir Katip Çelebi Üniversitesi Atatürk
Eğitim ve Araştırma Hastanesi, Klinik
Farmakoloji ve Toksikoloji Birimi, 35360,
Karabağlar, Izmir, Turkey
Tel +90 232 244 4444 ext 1798
Fax +90 232 245 0438
Email seawise@gmail.com

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Al-Saleem AI, Al-Jobair AM. Possible association between acetazolamide administration during pregnancy and multiple congenital malformations. *Drug Des Devel Ther*. 2016;10:1471–1476.
2. Scott WJ, Hirsch KS, DeSesso JM, Wilson JG. Comparative studies on acetazolamide teratogenesis in pregnant rats, rabbits, and rhesus monkeys. *Teratology*. 1981;24(1):37–42.
3. Kojima N, Naya M, Makita T. Effects of maternal acetazolamide treatment on body weights and incisor development of the fetal rat. *J Vet Med Sci*. 1999;61(2):143–147.
4. Holmes LB, Kawanishi H, Munoz A. Acetazolamide: maternal toxicity, pattern of malformations, and litter effect. *Teratology*. 1988;37(4):335–342.
5. Heinonen OP, Slone D, Shapiro S. *Birth Defects and Drugs in Pregnancy*. Littleton: Publishing Sciences Group; 1977.
6. Golan S, Maslovitz S, Kupferminc MJ, Kesler A. Management and outcome of consecutive pregnancies complicated by idiopathic intracranial hypertension. *Isr Med Assoc J*. 2013;15(4):160–163.
7. Falardeau J, Lobb BM, Golden S, Maxfield SD, Tanne E. The use of acetazolamide during pregnancy in intracranial hypertension patients. *J Neuroophthalmol*. 2013;33(1):9–12.

Authors' reply

Afnan I Al-Saleem¹

Asma M Al-Jobair²

¹Dental Department, Prince Sultan Military Medical City,

²Department of Pediatric Dentistry and Orthodontics, College of Dentistry, King Saud University, Riyadh, Saudi Arabia

Correspondence: Asma M Al-Jobair

Department of Pediatric Dentistry and Orthodontics, College of Dentistry, King Saud University, PO Box 60169, Riyadh 11545, Saudi Arabia

Tel +96 611 467 6648

Email aaljobair@ksu.edu.sa

Dear editor

Thank you for the opportunity to respond to the letter from Dr Keskin-Arslan and Dr Kaplan, which contained positive comments on our case report titled "Possible association between acetazolamide administration during pregnancy and multiple congenital malformations" published in *Drug Design, Development and Therapy* Journal in April 2016.¹

We thank the authors for their comments which served as an update on our paper and as they mentioned, expanded the current context of what we provided in the article. At the time, we chose to include only full-text articles and not just rely on abstracts. The articles the authors mentioned may be those papers that we could not access at the time.

Having provided the additional information makes the paper more informative and interesting now, and we are grateful to both of the authors.

Disclosure

The authors report no conflicts of interest in this communication.

Reference

1. Al-Saleem AI, Al-Jobair AM. Possible association between acetazolamide administration during pregnancy and multiple congenital malformations. *Drug Des Devel Ther*. 2016;10:1471–1476.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the *Drug Design, Development and Therapy* 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the *Drug Design, Development and Therapy* editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress